$4550
$2730
[Research Report] The pre-clinical CROs market size is expected to grow from US$ 4,282.2 million in 2018 to US$ 8,412.9 million by 2027; it is estimated to grow at a CAGR of 8.1% from 2019 to 2027.
Analyst’s ViewPoint
The pre-clinical CROs market aims to support compliance regulations across geographies. Once adopted, it provides a comprehensive knowledge-rich environment that enables early investigational new drug (IND). The pre-clinical CROs market analysis include driving factors such as rising prevalence of rare diseases and rising number of outsourcing activities by the pharmaceutical companies to CROs for drug development acting as the most impacting factors responsible for influential growth of pre-clinical CROs market. Further, technological advancements in the clinical research acts as a future trend for the market to grow during 2023-2028. According to the segmentation profiled in the report, based on service segment, toxicology segment accounts the highest share and based on end user, biopharmaceutical companies dominate the market recording maximum share.
Pre-clinical CRO is a support center that offers expertise in research & development intended for navigating a drug candidate through animal testing and advancing it into the clinical phase. Also, preclinical research services involve several studies related to assessing drug efficacy and safety in animal models and complete Investigational New Drug (IND) filing studies. Furthermore, the main objective of the pharmaceutical organization using a preclinical CRO is to achieve fast and effective delivery to the market.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Pre Clinical CROs Market: Strategic Insights
Market Size Value in US$ 4,282.2 Million in 2018 Market Size Value by US$ 8,412.9 Million by 2027 Growth rate CAGR of 8.1% from 2019-2027 Forecast Period 2019-2027 Base Year 2018
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Pre Clinical CROs Market: Strategic Insights
Market Size Value in | US$ 4,282.2 Million in 2018 |
Market Size Value by | US$ 8,412.9 Million by 2027 |
Growth rate | CAGR of 8.1% from 2019-2027 |
Forecast Period | 2019-2027 |
Base Year | 2018 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to AnalystThe main services under pre-clinical CROs involve:
- Project Management
- Medical Testing
- Toxicology
- Maximum Dosage Studies
- Regulatory Compliance
- Safety And Efficacy Reporting
- Quality Analysis
- Species Expertise
Furthermore, improvements in pre-clinical development result in reduced costs as well as timelines. For example, pharma companies reduce the time they take to reach FIH application by 40% or more, with drugs progressing from candidate nomination to the start of clinical trials in little as 12 to 15 months. Such timelines not only provide patients with rapid access to innovative medicines but also provides pharma companies to account for high revenue targets with a longer period of drug exclusivity in the market.
Market Insights
Rising Number of Outsourcing Activities by the Pharmaceutical Companies to CROs For Drug Development
Outsourcing of pharmaceutical services started in areas such as clinical development and manufacturing. Also, rapidly evolving market dynamics have encouraged pharmaceutical companies to broaden the scope of outsourcing activities across commercial activities. For example, pharmaceutical companies heavily invest in R&D to discover and develop new drugs, which can be time-consuming and expensive. Therefore, by outsourcing R&D to CDMO services, pharmaceutical companies can reduce capital expenditure and conserve cash. Furthermore, CDMOs can invest in specialized equipment and facilities that will support R&D resulting in pharmaceutical companies avoiding the need to make large capital investments.
Additionally, by reducing capital expenditures, outsourcing can help pharmaceutical companies to limit their financial risks. CDMOs can provide the necessary manufacturing capacity and expertise, allowing pharmaceutical companies to focus their resources on other business areas. Such aforementioned factors are responsible for the significant growth of the global pre-clinical CROs market during the forecast period.
Service Insights
Based on service, the pre-clinical CROs market is segmented as bio-analysis and DMPK studies, toxicology, and other services. The toxicology segment held the largest market share of 45.7% in 2019. Toxicology studies are used to characterize the toxicity profile of a drug by identifying its impact on organ structure and/or functionality. The toxicology studies reveal an assessment of the severity and reversibility of toxicity, as well as dose ranges and exposure. Also, pharmacological studies such as in-vivo preclinical toxicology studies are intended to assess the onset, severity, and duration of toxic effects, dose-dependency, and degree of reversibility (or irreversibility). Also, top companies like IITRI is a high-quality provider of preclinical toxicology and drug safety evaluation services in accordance with GLP standards. Also, the company provides a full range of in-vivo toxicology testing services that support submissions to the Food and Drug Administration (FDA) and other regulatory agencies involving complete IND-enabling programs and chemical toxicity assessments. Such aforementioned factors are responsible for influential segmental growth thereby dominating the overall market growth during the forecast period.
End User Insights
Based on end user, the global pre-clinical CROs market is segregated as biopharmaceutical companies, government & academic institutes, and medical device companies. The biopharmaceutical companies segment accounted largest market share of 50.25% in 2019. Pre-clinical development benefits from advancing new drug application (NDA) resulting in accelerating innovation, value, and improve quality of innovative products by the biopharmaceutical companies. Such untapped potential will increase the exposure of preclinical development. Furthermore, with pre-clinical research progressing from target identification early discovery of new drugs, experiments generating data, modulation of targets, manufacturing, improves resulting in investigational new drug (IND). Therefore, leading biopharmaceutical companies are searching for new ways to streamline processes and practices in pre-clinical development for new drug discoveries. Such aforementioned factors are responsible for influential segmental growth thereby dominating the overall market growth during the forecast period.
Pre-clinical CROs Market, by Service – 2019 and 2027
Regional Analysis
North America dominated the pre-clinical CROs market accounting maximum share. The market growth in this region is attributed due to presence of large players launching innovative product launches particularly pre-clinical CROs and continuous product introduction in the region. Among North America region, the US records maximum share of 60% for the pre-clinical CROs solution. As per the American Association for the Advancement of Science (AAAS) report, US$28 billion is spent in the US annually on pre-clinical research. With such high expenditure on pre-clinical research, US pharma companies extract useful information about treatment for specific or rare diseases. With promising pre-clinical research studies, the US FDA permits testing the treatment among the infected patient population.
Likewise, Asia Pacific is expected to account highest CAGR of 12.0% for the global pre-clinical CROs market during the forecast period. Among Asia Pacific region, China will account maximum CAGR for the global pre-clinical CROs market during the forecast period. The attributing factors involve investigational new drug (IND) applications and new drug applications (NDAs) intended for innovative drugs (that were applied for and approved in China between January 2010 and December 2020). The aforementioned factor is a standalone factor responsible for growth of pre-clinical CROs market in Asia Pacific region during the forecast period.
The report comprises leading players operating in the global pre-clinical CROs market. These involve LabCorp, Charles River Laboratories, Eurofins Scientific, PRA Health Sciences, WuXi AppTec, Medspace, Inc., Pharmaceutical Product Development, LLC., Paraxel International Corporation, ICON Plc, and MD Biosciences.
In July 2022, Biogen, Inc. announced that USFDA has accepted a new drug application (NDA) for "Tofersen", an investigational drug for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). ALS is a rare, progressive and fatal neurodegenerative disease that results in the loss of motor neurons in the brain and spinal cord that are responsible for controlling voluntary muscle movement.
Company Profiles
- LabCorp
- Charles River Laboratories
- Eurofins Scientific
- PRA Health Sciences
- WuXi AppTec
- Medspace, Inc.
- Pharmaceutical Product Development, LLC.
- Paraxel International Corporation
- ICON Plc
- MD Biosciences.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Service, End User, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
The List of Companies
- Covance, Inc.
- Charles River
- Eurofins Scientific
- PRA Health Sciences
- WuXi AppTec
- Medpace, Inc.
- Pharmaceutical Product Development, LLC
- Parexel International Corporation
- ICON Plc
- MD Biosciences
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Pre Clinical CROs Market
Sep 2019
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2019
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Sep 2019
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Sep 2019
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2019
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2019
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Sep 2019
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Sep 2019
Drug Delivery Market
Forecast to 2028 - Global Analysis By Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular Drug Delivery), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and End User (Hospitals and Clinics, Home Care Settings, and Other End User)